CROI 11 (Retrovirus) 2004

11th Conference on Retroviruses and Opportunistic Infections (CROI), 8-11 February 2004, San Francisco

HIV-associated dementia and cognitive dysfunction

Diabetes and HIV and HCV; aging/HIV and diabetes

Treatment with generics: tolerability, safety and resistance

11th Conference on Retroviruses and Opportunistic Infections (CROI)

Drug levels can persist for more than two weeks after stopping efavirenz

Race affects absorption and clearance of efavirenz

Triple PI interactions: atazanavir increases saquinavir levels in ritonavir-boosted once-daily combination

Triple PI interactions: fosamprenavir and Kaletra interaction is difficult to overcome

Ribavirin (RBV) does not alter intracellular levels of AZT, 3TC or d4T

COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation

Studies of new pipeline drugs

Little benefit seen for treatment during acute infection

Summary of resistance studies at Retrovirus

Update on peripheral neuropathy in HIV-infection

Smoking marijuana provides analgesic effect on HIV neuropathy

Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure

Low-dose rHGH maintains reductions in abdominal fat for 60 weeks

Rosiglitazone shows no benefit for lipoatrophy

Hypertension related to HAART in HIV-positive women

Testosterone therapy for women with low androgen levels or body weight

Nevirapine, pregnancy and adverse events

Prior nevirapine exposure for pregnant women can contribute to treatment failure

Conflicting findings with HAART use in pregnancy and prematurity

Antiretrovirals, mode of delivery and transmission risk

Tenofovir studies in children

Increase of non-AIDS defining cancers in HOPS cohort

HIV/HCV coinfection: superiority of pegylated interferon plus ribavirin, but lower response rate compared to mono-infected patients, especially for genotype-1

Epoetin-alfa improves interferon/ribavirin-associated anaemia